

Date: May 9, 2025

To
The Manager
Department of Corporate Services
BSE Limited
25th Floor, P. J. Towers,
Dalal Street, Mumbai – 400001
Scrip Code: 543064

To
The Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex
Bandra (E), Mumbai – 400051
Scrip Symbol: SUVENPHAR

Sub: Allotment of shares pursuant to Scheme of Amalgamation - Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”)

Ref: Scheme of Amalgamation of Cohance Lifesciences Limited (“Transferor Company” / “Cohance”) with and into Suven Pharmaceuticals Limited (“Transferee Company” / “the Company”) under Sections 230 to 232 of the Companies Act, 2013 (“Act”), the Companies (Compromises, Arrangements and Amalgamations) Rules, 2016 and other rules and regulations framed thereunder (“Scheme of Amalgamation”)

Dear Sir/Madam,

This is with reference to, and in furtherance of our disclosures dated February 29, 2024, October 22, 2024, October 26, 2024, November 28, 2024, March 27, 2025, April 22, 2025 and April 25, 2025, in connection with the Scheme of Amalgamation, as approved and sanctioned by the Hon’ble National Company Law Tribunal, Mumbai bench (“NCLT”) *vide* its order dated March 27, 2025.

Please further note that the Company *vide* letter dated May 7, 2025 has intimated change of name of “**Suven Pharmaceuticals Limited**” to “**Cohance Lifesciences Limited**” pursuant to the said Scheme of Amalgamation, as approved by the Ministry of Corporate Affairs, Government of India.

In this connection, we would like to inform you that in terms of the Scheme of Amalgamation, the Company has, today, i.e. on May 9, 2025, approved the allotment of 12,80,02,184 equity shares of the Company of face value Re. 1/- each, to the eligible shareholders of the Transferor Company as on the Record Date (which has been intimated to the exchanges by way of letter dated April 25, 2025), in the share exchange ratio of 11:295 i.e. 11 (eleven) fully paid-up equity shares of face value Re.1/- (Rupee one) each of the Transferee Company for every 295 (two hundred ninety-five) fully paid-up equity shares of face value Rs.10/- (Rupees Ten) each held by such eligible shareholders in Transferor Company, in terms with the Scheme of Amalgamation. These equity shares so allotted shall rank *pari-passu* with the existing equity shares of the Company. These equity shares are proposed to be listed and traded on BSE Limited and the National Stock Exchange of India Limited.

The above allotment includes the following:

- a) 18 fully paid-up equity shares of the Company of face value Re. 1/- each, allotted to the Fractional Share Demat Account, towards fractional entitlements of eligible shareholders of Transferor Company, as per

Cohance Lifesciences Limited
(Formerly, Suven Pharmaceuticals Limited)

Corporate Office: 202, A-Wing, Galaxy Towers, Plot No.1, Hyderabad Knowledge City, TSIC, Raidurg, Hyderabad – 500081, Telangana, India.
Tel: +91 40 2354 9414 / 3311

Registered Office: 215 Atrium, C Wing, 8th Floor, 819-821, Andheri Kurla Road, Chakala, Andheri East, Chakala MIDC, Mumbai – 400093, Maharashtra, India.
Tel: +91 22 6153 9999

CIN: L24299MH2018PLC422236 | Website: www.suvenpharm.com | Company Email: info@suvenpharm.com



the Share Exchange Ratio mentioned above, in accordance with the terms of the Scheme of Amalgamation.

- b) 34,906 fully paid-up equity shares of the Company of face value Re. 1/- each, allotted to Unclaimed Securities – Suspense Escrow account, representing in aggregate the equity shares of eligible shareholders of Transferor Company whose shares were lying in Unclaimed Share Demat Account of Transferor Company as on the Record Date and whose individual demat account details are yet to be made available to the Company as on the date of allotment, in accordance with the terms of the Scheme of Amalgamation.

This disclosure is being made in terms of Regulation 30 of the SEBI Listing Regulations, as amended from time to time.

We request to take the aforesaid disclosure on your records.

Thanking you.

Yours faithfully,
For **Cohance Lifesciences Limited**
(Formerly, Suven Pharmaceuticals Limited)

Kundan Kumar Jha
Company Secretary, Compliance Officer and Head-Legal

